CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. Fundamental Analysis
CANbridge Pharmaceuticals Inc. (1228.HK) shows weak financial fundamentals with a PE ratio of 60.57, profit margin of 29.65%, and ROE of -3.63%. The company generates $0.0B in annual revenue with weak year-over-year growth of -17.27%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 15.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 1228.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1228.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate1228.HK shows balanced valuation metrics.
Growth Score
Weak1228.HK faces weak or negative growth trends.
Financial Health Score
Moderate1228.HK shows balanced financial health with some risks.
Profitability Score
Weak1228.HK struggles to sustain strong margins.
Key Financial Metrics
Is 1228.HK Expensive or Cheap?
P/E Ratio
1228.HK trades at 60.57 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 1228.HK's PEG of 0.11 indicates potential undervaluation.
Price to Book
The market values CANbridge Pharmaceuticals Inc. at -2.63 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -10.67 times EBITDA. This is generally considered low.
How Well Does 1228.HK Make Money?
Net Profit Margin
For every $100 in sales, CANbridge Pharmaceuticals Inc. keeps $29.65 as profit after all expenses.
Operating Margin
Core operations generate -1.85 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-3.63 in profit for every $100 of shareholder equity.
ROA
CANbridge Pharmaceuticals Inc. generates $8.96 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
CANbridge Pharmaceuticals Inc. generates limited operating cash flow of $-6.28M, signaling weaker underlying cash strength.
Free Cash Flow
CANbridge Pharmaceuticals Inc. generates weak or negative free cash flow of $-6.32M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.01 in free cash annually.
FCF Yield
1228.HK converts -0.89% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
60.57
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.11
vs 25 benchmark
P/B Ratio
Price to book value ratio
-2.63
vs 25 benchmark
P/S Ratio
Price to sales ratio
15.99
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-0.05
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.24
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.04
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.32
vs 25 benchmark
How 1228.HK Stacks Against Its Sector Peers
| Metric | 1228.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 60.57 | 28.32 | Worse (Expensive) |
| ROE | -3.63% | 733.00% | Weak |
| Net Margin | 29.65% | -53055.00% (disorted) | Strong |
| Debt/Equity | -0.05 | 0.38 | Strong (Low Leverage) |
| Current Ratio | 0.24 | 4.03 | Weak Liquidity |
| ROA | 8.96% | -19488.00% (disorted) | Weak |
1228.HK outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews CANbridge Pharmaceuticals Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
833.33%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
67.24%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
84.37%
Industry Style: Defensive, Growth, Innovation
High Growth